Efficacy and safety of sequential moxifloxacin for treatment of community-acquired pneumonia associated with atypical pathogens

In two prospective, randomized studies intravenous (IV)/oral (PO) moxifloxacin (400 mg q.i.d.) was compared to IV/PO antimicrobial comparator agents for the treatment of hospitalized patients with community-acquired pneumonia. Reported here are the pooled data for the sub-population with atypical pa...

Full description

Saved in:
Bibliographic Details
Published in:European journal of clinical microbiology & infectious diseases 2004-10, Vol.23 (10), p.772-775
Main Authors: HOEFFKEN, G, TALAN, D, LARSEN, L. S, PELOQUIN, S, CHOUDHRI, S. H, HAVERSTOCK, D, JACKSON, P, CHURCH, D
Format: Article
Language:English
Subjects:
Administration, Oral
Adolescent
Adult
Aged
Aged, 80 and over
Anti-Infective Agents - administration & dosage
Anti-Infective Agents - adverse effects
Anti-Infective Agents - therapeutic use
Antibacterial agents
Antibiotics. Antiinfectious agents. Antiparasitic agents
Aza Compounds - administration & dosage
Aza Compounds - adverse effects
Aza Compounds - therapeutic use
Biological and medical sciences
Clinical trials
Community-Acquired Infections - drug therapy
Female
Fluoroquinolones
Humans
Infectious diseases
Injections, Intravenous
Male
Medical sciences
Middle Aged
Pathogens
Pharmacology. Drug treatments
Pneumonia
Pneumonia, Bacterial - drug therapy
Pneumonia, Bacterial - microbiology
Quinolines - administration & dosage
Quinolines - adverse effects
Quinolines - therapeutic use
Retrospective Studies
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In two prospective, randomized studies intravenous (IV)/oral (PO) moxifloxacin (400 mg q.i.d.) was compared to IV/PO antimicrobial comparator agents for the treatment of hospitalized patients with community-acquired pneumonia. Reported here are the pooled data for the sub-population with atypical pathogens. Of 101 intent-to-treat patients with atypical pathogens, a total of 39 moxifloxacin-treated and 47 comparator-treated subjects were microbiologically valid and included in the analysis. Clinical and bacteriological success rates were 95% for the moxifloxacin-treated and 94% for the comparator-treated subjects at the test-of-cure visit. The results indicate IV/PO moxifloxacin (400 mg q.i.d.) is an effective monotherapy for patients with CAP due to atypical pathogens.
ISSN:0934-9723
1435-4373
DOI:10.1007/s10096-004-1214-5